1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAmyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) is sponsored by Department of Defense (DoD). Supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in ALS.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award Agency: Defense Health Agency Contracting Activity - DHACA Assistance Listings: 12. 420 -- Military Medical Research and Development Last Updated: May 13, 2026 View version history on Grants.
gov Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS).
Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. To meet the intent of the funding opportunity, applications must address ONE or BOTH of the following focus areas: Clinical Biomarkers: Identification, development, and/or validation of promising biomarkers for ALS.
Biomarkers may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes: Identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include optimization of current outcome measures already in use.
Both focus areas are permitted to utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Distinctive Features: Applications proposing prospective biospecimen collection or participant enrollment are required to incorporate a Community Collaboration, as described in Attachment 9.
Grantor contact information File name Description Last updated HT9425FY25ALSRPCOBA_updated.
pdf FY25 ALSRP COBA Program Announcement May 23, 2025 12:49 PM UTC Link to additional information Archived: September 26, 2025 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Science technology and other research and development Your account requires additional identity verification.
According to the current listing, eligibility includes: U. S. and foreign entities are eligible to apply. Confirm the full requirements in the official notice before applying.
Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) is funded by Department of Defense (DoD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award is sponsored by Defense Health Agency Contracting Activity - DHACA. Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery.
DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Program is sponsored by Dept. of the Army -- USAMRAA. The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment of Amyotrophic Lateral Sclerosis.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe Department's FY26 SBIR/STTR Release 3 opened June 24 with roughly 37 topics across DARPA, the Navy, the Air Force, and the defense components, all closing July 22. The compressed four-week window is unforgiving, but the bigger mistake founders make is treating every component the same. Here is how to read the release, the eligibility rules that disqualify good companies, and why the component you target matters more than the topic you pick.
Read article